Larson Jessica, Twohig Patrick, Hutchins Kathryn
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.
Division of Gastroenterology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.
ACG Case Rep J. 2023 Feb 22;10(2):e00993. doi: 10.14309/crj.0000000000000993. eCollection 2023 Feb.
Tumor necrosis factor-α inhibitors are monoclonal antibodies that are commonly used in the treatment of inflammatory bowel disease. A rare side effect of these biological agents is chronic inflammatory demyelinating polyneuropathy, which is a debilitating disease characterized by weakness, sensory dysfunction, and diminished or absent reflexes. We present the first reported case of chronic inflammatory demyelinating polyneuropathy after treatment with the tumor necrosis factor-α inhibitor biosimilar, infliximab-dyyp (Inflectra).
肿瘤坏死因子-α抑制剂是常用于治疗炎症性肠病的单克隆抗体。这些生物制剂的一种罕见副作用是慢性炎症性脱髓鞘性多发性神经病，这是一种使人衰弱的疾病，其特征为虚弱、感觉功能障碍以及反射减弱或消失。我们报告了首例使用肿瘤坏死因子-α抑制剂生物类似药英夫利昔单抗-dyyp（英利昔单抗）治疗后发生慢性炎症性脱髓鞘性多发性神经病的病例。
